The Retaining Access and Restoring Exclusivity (RARE) Act amends section 527 of the Federal Food, Drug, and Cosmetic Act to change how orphan‑drug exclusivity is defined and applied. Instead of blocking approvals for any drug treating the same rare disease or condition, the bill ties exclusivity to the specific FDA‑approved use or indication for which the original drug received its 7‑year orphan exclusivity, and explicitly defines “approved use or indication” as the use approved under section 505 or licensed under section 351.
The change is applied to all drugs with orphan designation regardless of when they were designated or approved. For sponsors, regulators, payers and patients, that shifts the legal fence around exclusivity from an entire disease to the narrower language of approved labeling — with immediate implications for competition, pricing, labeling strategy, and litigation risk.
At a Glance
What It Does
The bill replaces language in 21 U.S.C. 360cc that referred to the “same disease or condition” with language that limits exclusivity to the “same approved use or indication,” and it adds a new definition tying that phrase to approvals under section 505 and licenses under section 351. It leaves the 7‑year orphan exclusivity term intact.
Who It Affects
Primary targets are current and future sponsors of drugs designated under the orphan provisions, applicants for competing drugs (including generics and biosimilars), and FDA review divisions that must compare proposed labeling to existing approvals. Payers, clinicians, and patients who rely on therapeutic options in small populations will also see downstream effects.
Why It Matters
By anchoring exclusivity to FDA‑approved labeling rather than the broader disease label, the bill narrows the barrier to entry for therapies addressing different indications or subpopulations within the same rare disease — a change that can materially alter commercial exclusivity, pricing leverage, and R&D incentives.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The RARE Act edits the statutory text that governs orphan‑drug exclusivity so the blocking effect applies only to the exact use or indication for which an orphan drug received approval, not to the whole rare disease category. Practically, that means when the FDA evaluates an application for a second drug in the same rare disease, the agency will compare the applicant’s proposed indication language to the earlier drug’s label language to decide whether the 7‑year orphan exclusivity blocks approval.
The bill adds an explicit definition: an “approved use or indication” is the use approved under the standard drug approval pathway (section 505) or the biologic licensing pathway (section 351). That wording pushes the legal comparison into the mechanics of labeling and licensure: precise claim language, patient population descriptions, and intended use statements will determine whether exclusivity applies.
Sponsors can expect labeling strategy to become a primary defensive tool.Importantly, the amendment applies retroactively to any drug with an orphan designation, regardless of when it was designated or approved. That creates an immediate regulatory and commercial effect: some drugs that previously blocked competitors across an entire disease may no longer block applications that target distinct indications or subpopulations.
The FDA will need to adapt its review practices, and sponsors will face both opportunities for entrant products and new pressures to broaden or adjust labels to protect exclusivity.The statute does not change the length of orphan exclusivity, the criteria for receiving orphan designation, or patent protections — it changes only the legal scope of what the exclusivity blocks. That surgical change reallocates where disputes over market exclusivity will occur: not in the duration of protection, but in the contours of approved indications and in post‑approval labeling strategies.
Expect litigation and administrative disputes around whether a proposed indication is meaningfully the same as an existing one.
The Five Things You Need to Know
The bill edits 21 U.S.C. 360cc (section 527) to replace references to the “same disease or condition” with “same approved use or indication” in multiple subsections.
It adds a new subsection defining “approved use or indication” as a use approved under section 505 (drugs) or licensed under section 351 (biologics).
The amendments apply retroactively to any drug designated under section 526, regardless of the dates of designation or approval.
The bill does not change the 7‑year orphan exclusivity term or the criteria for orphan designation; it only narrows the scope of what exclusivity prevents.
Implementation will hinge on label language: margin differences in indication wording can determine whether a later application is blocked by existing orphan exclusivity.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Replace disease‑level exclusivity language with indication‑level language
The bill instructs specific edits to subsection (a) through (c)(1) of 21 U.S.C. 360cc, striking phrases that referred to the “same disease or condition” and replacing them with references to the “same approved use or indication” or the use “for which such 7‑year period applies.” Mechanically, the FDA’s blocking test will move from a disease taxonomy to a side‑by‑side comparison of approved indications and proposed labeling. For reviewers and sponsors, that transforms a relatively blunt exclusivity rule into a fact‑intensive inquiry about label copy, patient population descriptions, and intended uses.
New statutory definition of ‘approved use or indication'
The bill adds subsection (f) to define the critical new term: an approved use or indication is the use approved under section 505 or licensed under section 351. That ties the exclusivity comparison explicitly to the formal approval/licensure pathways rather than to broader clinical or disease definitions. In practice, the definition puts legal weight behind the literal language of approvals — and invites strategic behavior around initial label drafting and later supplemental indications.
Retroactive application to all designated drugs
The statutory change applies to any drug designated under section 526 regardless of when designation or approval occurred. By making the amendment retroactive, the bill immediately alters the exclusivity landscape for existing orphan drugs: some previously blocked applications may now proceed if their proposed indications differ from the defined approved uses. That raises transitional questions for enforcement, pending applications, and market entry timing that the FDA and stakeholders will need to resolve administratively or through litigation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Manufacturers of follow‑on drugs (small molecule and biologic competitors) — They can seek approval for distinct indications or narrowly framed subpopulations within the same rare disease without being automatically blocked by an earlier drug's orphan exclusivity.
- Payers and health systems — Increased competition within a rare‑disease category can lead to additional therapeutic choices and potential pricing pressure, improving bargaining leverage for formularies and insurers.
- Patients in underserved subpopulations — Patients whose needs differ from the specific approved indication may gain access to treatments that were previously barred by disease‑level exclusivity.
- Generic and biosimilar applicants — Where exclusivity no longer covers a proposed indication, generic or biosimilar pathways may face fewer statutory barriers to approval for alternatives targeting different labeled uses.
Who Bears the Cost
- Existing orphan‑drug sponsors — Narrower exclusivity increases the risk of competing approvals within what they considered their market, reducing monopolistic pricing power and potentially shortening effective commercial exclusivity despite the unchanged 7‑year term.
- Investors in orphan‑drug development — Retroactive narrowing can change the risk/return calculus for investments made under the expectation of disease‑level exclusivity, creating valuation and financing uncertainty.
- The FDA — Review divisions will face a heavier workload and more granular legal determinations about label language, intended use, and whether a proposed indication is meaningfully the same as an approved one.
- Legal teams and companies — Expect increased litigation and administrative petitions over indication‑scope disputes, shifting compliance and advisory costs toward more label‑focused legal strategy.
Key Issues
The Core Tension
The bill pits two legitimate goals against each other: expanding patient access and competition within rare‑disease markets by narrowing statutory exclusivity, versus preserving strong, predictable exclusivity that underwrites high‑risk investment in orphan drug development; retroactive application intensifies the dilemma by changing the value of existing approvals while leaving other protection mechanisms (like patents) unchanged.
The central operational question created by the bill is how to define the boundary between an “approved indication” and a related use within the same disease. Because the statute anchors exclusivity to approval language under sections 505 and 351, the specific phrasing of labels will become a litigation focal point.
Sponsors will have incentives to draft broadly worded indications at initial approval or to pursue expansive supplemental indications — behavior that could counteract the bill’s access goals by encouraging overbroad claims to preserve exclusivity. Conversely, companies may narrowly carve indications to retain exclusivity in valuable patient cohorts, fragmenting the market.
Retroactivity raises a second set of trade‑offs. Applying the change to previously approved drugs addresses immediate access concerns, but it also undermines prior business expectations and could chill future investment in orphan therapeutics unless investors receive other assurances.
The bill leaves patent law and other exclusivities intact, which means that in many cases patent protection, citizen petitions, or REMS and labeling strategies will remain critical tools for sponsors even if statutory orphan exclusivity narrows. Finally, the FDA will likely need clear administrative guidance on transitional procedures for pending applications and settled expectations — absent that guidance, the statute is likely to spawn a wave of lawsuits testing how granular the “indication” comparison must be.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.